ABVC BioPharma announced the appointment of Dr. Uttam Yashwant Patil as the new CEO. Uttam is very familiar with ABVC and their subsidiaries, because of his role as Chief Operating Officer & Chief Scientific Officer of BioKey, Inc., a GMP-certified facility owned by ABVC that provides its clients with integrated pharmaceutical services, including early-phase product development, formulation development, analytical development & drug product manufacturing. He is also the R&D Manager for an ABVC collaborative program, committed to developing new plant-based drugs and combination cancer therapies to provide better medical assistance for improving the patient’s quality of life.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABVC:
- ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth
- ABVC subsidiary projects $1M proceeds from dietary supplement production
- ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production
- ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
- ABVC BioPharma enrolls first subject for ADHD Phase II Part 2 study